Loading...

FITC anti-mouse CD62L Antibody

Pricing & Availability
Clone
MEL-14 (See other available formats)
Regulatory Status
RUO
Other Names
L-selectin, LECAM-1, Ly-22, LAM-1, MEL-14
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
MEL-14
C57BL/6 bone marrow cells stained with MEL-14 FITC
  • MEL-14
    C57BL/6 bone marrow cells stained with MEL-14 FITC
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
104405 50 µg 52€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
104406 500 µg 164€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD62L is a 74-95 kD glycoprotein also known as L-selectin, LECAM-1, Ly-22, LAM-1, and MEL-14. It is a member of the selectin family and is expressed on the majority of B and naïve T cells, a subset of memory T cells, monocytes, granulocytes, most thymocytes, and a subset of NK cells. CD62L is important in lymphocyte homing to high endothelial venules (HEV) in peripheral lymph nodes and leukocyte "rolling" on activated endothelium. CD62L also contributes to neutrophil emigration at inflammatory sites. CD62L is rapidly shed from lymphocytes and neutrophils upon cellular activation and the expression levels of CD62L (in conjunction with other markers) have been used to distinguish naïve, effector, and memory T cells. CD62L has been reported to interact with CD34, GlyCAM-1, and MAdCAM-1.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
C3H/eb mouse B lymphoma 38C-13
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation1-3, complement-dependent cytotoxicity4, in vivo and in vitro blocking of adhesion1-3,5, and immunohistochemical staining of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections6. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. Nos. 104457-104462).

Application References
  1. Gallatin WM, et al. 1983. Nature 304:30. (IP, Block)
  2. Siegelman MH, et al. 1990. Cell 61:611. (IP, Block)
  3. Lewinsohn DM, et al. 1987. J. Immunol. 138:4313. (IP, Block)
  4. Iwabuchi K, et al. 1991. Immunobiology 182:161. (CMCD)
  5. Pizcueta P, et al. 1994. Am. J. Pathol. 145:461.
  6. Reichert RA, et al. 1986. J. Immunol. 136:3535. (IHC, FC)
  7. Olver S, et al. 2006. Cancer Res. 66:571.
  8. Fukushima A, et al. 2006. Invest. Ophthalmol. Vis. Sci. 47:657. PubMed
  9. Benson MJ, et al. 2007. J. Exp. Med. doi:10.1084/jem.20070719. (FC) PubMed
  10. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed
  11. Lee JW, et al. 2006. Nature Immunol. 8:181.
  12. Shigeta A, et al. 2008. Blood 112:4915 (FC) PubMed
  13. de Vries VC, et al. 2009. Am. J. Transplant. 9:2270 PubMed
Product Citations
  1. Wu J et al. 2017. Immunity. 47(6):1114-1128 . PubMed
  2. Zelenka T, et al. 2022. Nat Commun. 13:6954. PubMed
  3. Furuya Y, et al. 2014. J Virol. 88:9166. PubMed
  4. Qi Z, et al. 2022. Nat Commun. 13:182. PubMed
  5. Park JH, et al. 2022. STAR Protoc. 3:101607. PubMed
  6. Burrack AL, et al. 2019. Cell Rep. 28:2140. PubMed
  7. Kubo M, et al. 2018. Oncol Rep. 39:417. PubMed
  8. Andreas N, et al. 2021. Arthritis Res Ther. 23:222. PubMed
  9. Israelow B, et al. 2021. Sci Immunol. 6:eabl4509. PubMed
  10. Achmus L, et al. 2020. Front Neurol. 11:577971. PubMed
  11. Klarquist J, et al. 2021. Cell Rep. 36:109591. PubMed
  12. Menzel L, et al. 2021. Cell Rep. 37:109878. PubMed
  13. Chen Z, et al. 2017. Mucosal Immunol. 10:58. PubMed
  14. Harada Y, et al. 2022. iScience. 25:104021. PubMed
  15. Xu X, et al. 2021. J Nanobiotechnology. 19:376. PubMed
  16. Zhuang Z, et al. 2021. J Exp Med. 218:00:00. PubMed
  17. Flaherty S, Reynolds J 2015. J Vis Exp. 98: 52739. PubMed
  18. Prüfer S, et al. 2014. Immunobiology. 219:87. PubMed
  19. McCreedy DA et al. 2018. eNeuro. 5(4) pii: ENEURO. PubMed
  20. Yang K, et al. 2022. J Clin Invest. 132:. PubMed
  21. Wang B, et al. 2022. Nat Commun. 13:3821. PubMed
  22. Cuburu N, et al. 2019. J Immunol. 202:1250. PubMed
  23. Zhang B, et al. 2021. Nat Biomed Eng. 5:1288. PubMed
  24. Espinosa JR, et al. 2018. Front Immunol. 9:1371. PubMed
  25. Hu Q, et al. 2018. Nat Biomed Eng. 0.660416667. PubMed
  26. Cutler CE, et al. 2019. Glycobiology. 29:776. PubMed
  27. Wan X, et al. 2018. Nature. 560:107. PubMed
  28. Kishore M et al. 2017. Immunity. 47(5):875-889 . PubMed
  29. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  30. Brigas HC, et al. 2021. Cell Reports. 36(9):109574. PubMed
  31. Green WD, et al. 2022. J Leukoc Biol. 111:147. PubMed
  32. Cook KD, et al. 2015. Immunity. 43:703-714. PubMed
  33. Wang Y, et al. 2020. Cell Death Dis. 1.169444444. PubMed
  34. Ying Zhang et al. 2017. Cancer cell. 32(3):377-391 . PubMed
  35. Nowill AE, et al. 2019. J Immunol. 203:1298. PubMed
  36. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  37. Kondo M, et al. 2016. J Immunol. 196: 563 - 572. PubMed
  38. Joubert IA, et al. 2020. Vaccine. 38:1015. PubMed
  39. Wu J, et al. 2021. STAR Protoc. 2:101022. PubMed
  40. Liu W, et al. 2022. J Clin Invest. 132: . PubMed
  41. Chakraborty M, et al. 2021. Cell Reports. 34(2):108609. PubMed
  42. Sema Kurtulus et al. 2018. Immunity. 50(1):181-194 . PubMed
  43. Yu H, et al. 2021. Cell Death Dis. 13:1. PubMed
  44. Wagner AK, et al. 2022. iScience. 25:105137. PubMed
  45. Winter C, et al. 2018. Cell Metab. 28:175. PubMed
  46. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  47. Malenica I, et al. 2021. Nat Commun. 12:5209. PubMed
  48. Charlton J, et al. 2015. PLoS One. 10:119200. PubMed
  49. Kashiwakura Y, et al. 2020. Clinical & Experimental Immunology. 202(1):119-135. PubMed
  50. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  51. Mohammed RN, et al. 2019. Sci Rep. 4.185416667. PubMed
  52. Chen S, et al. 2018. Nat Commun. 9:5298. PubMed
  53. Stienne C, et al. 2022. Cell Rep. 38:110553. PubMed
  54. Bonaccorsi-Riani E, et al. 2015. PLoS One. 10: 0136106. PubMed
RRID
AB_313092 (BioLegend Cat. No. 104405)
AB_313093 (BioLegend Cat. No. 104406)

Antigen Details

Structure
Selectin, 95 kD (neutrophils) or 74 kD (lymphocytes)
Distribution

Subsets of B and T cells, monocytes, granulocytes, subset of NK cells

Function
Lymphocyte homing to HEV, rolling on activated endothelium
Ligand/Receptor
CD34, GlyCAM-1, MAdCAM-1
Cell Type
B cells, Granulocytes, Monocytes, Neutrophils, NK cells, T cells, Tregs
Biology Area
Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity
Molecular Family
Adhesion Molecules, CD Molecules
Antigen References

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Kishimoto TK, et al. 1990. P. Natl. Acad. Sci. USA 87:2244.
3. Tedder TF, et al. 1995. J. Exp. Med. 181:2259.

Gene ID
20343 View all products for this Gene ID
UniProt
View information about CD62L on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 1    Revision Date: 11-30-2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account